Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
Authors
Keywords
Blood glucose–lowering drugs, Type 2 diabetes mellitus, Stroke, AMI, Meta-analysis, Cardiovascular safety, Pharmacoepidemiology, Observational studies
Journal
BMC Cardiovascular Disorders
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-01-15
DOI
10.1186/s12872-016-0187-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
- (2014) Cristina Varas-Lorenzo et al. BMC Cardiovascular Disorders
- Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations
- (2014) Elisabetta Patorno et al. DIABETOLOGIA
- Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank
- (2014) Andrea V Margulis et al. Clinical Epidemiology
- Cardiovascular Effects of Diabetes Drugs: Emerging From the Dark Ages
- (2013) Steven E. Nissen ANNALS OF INTERNAL MEDICINE
- Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus
- (2013) Christianne L. Roumie et al. ANNALS OF INTERNAL MEDICINE
- Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
- (2013) Richard G. Bach et al. CIRCULATION
- Rosiglitazone and Cardiovascular Outcomes
- (2013) Hertzel C. Gerstein CIRCULATION
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETIC MEDICINE
- The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience
- (2013) William R. Hiatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality in diabetes compared with previous cardiovascular disease: A gender-specific meta-analysis
- (2012) C. Lee et al. DIABETES & METABOLISM
- A new “Comparative Effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone
- (2012) Richard Tannen et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Incidence of Cardiovascular Events in Which 2 Thiazolidinediones Are Used as Add-on Treatments for Type 2 Diabetes Mellitus in a Taiwanese Population
- (2011) Chih-Chieh Chou et al. CLINICAL THERAPEUTICS
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
- (2011) David R. Whiting et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Development of the RTI item bank on risk of bias and precision of observational studies
- (2011) Meera Viswanathan et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study
- (2011) Henriette Thisted Horsdal et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population
- (2010) Debra A. Wertz et al.
- The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database
- (2010) Najat Ziyadeh et al. CLINICAL THERAPEUTICS
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
- (2010) David J. Graham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2010) Ronen Loebstein et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)
- (2010) Dori Bilik et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Pioglitazone and the Risk of Myocardial Infarction and Other Major Adverse Cardiac Events: A Meta-Analysis of Randomized, Controlled Trials
- (2009) Nagapradeep Nagajothi et al. AMERICAN JOURNAL OF THERAPEUTICS
- Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
- (2009) J. S. Brownstein et al. DIABETES CARE
- Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study
- (2009) Henriette T. Horsdal et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
- (2009) Fei-Yuan Hsiao et al. DRUG SAFETY
- Cardiac safety profile of rosiglitazone
- (2009) Edoardo Mannucci et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis
- (2009) Zeina A. Habib et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction
- (2009) David D Dore et al. PHARMACOTHERAPY
- Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
- (2009) Colin R. Dormuth et al. PLoS One
- Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
- (2008) Wolfgang C. Winkelmayer et al. ARCHIVES OF INTERNAL MEDICINE
- Is diabetes a coronary risk equivalent? Systematic review and meta-analysis
- (2008) U. Bulugahapitiya et al. DIABETIC MEDICINE
- Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study
- (2008) H. T. Horsdal et al. DIABETOLOGIA
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
- (2008) Alexander M. Walker et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients
- (2008) Carol E. Koro et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone
- (2008) Alexander Cobitz et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now